公开(公告)号：US11590124B2

公开(公告)日：2023-02-28

申请号：US17473860

申请日：2021-09-13

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/138 ,  A61K31/4748 ,  A61K9/00

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20220409639A1

公开(公告)日：2022-12-29

申请号：US17749887

申请日：2022-05-20

申请人： Diana Driscoll

发明人： Diana Driscoll

IPC分类号： A61K31/685 ,  A61K31/205 ,  A61K31/14 ,  A61P27/04 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06

摘要： The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

公开(公告)号：US20220323464A1

公开(公告)日：2022-10-13

申请号：US17531404

申请日：2021-11-19

申请人： The Brain Health Project, LLC

发明人： Morris Notelovitz

IPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/4748 ,  A61K31/353 ,  A61K31/592 ,  A61K31/566 ,  G01N33/68

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US20220296672A1

公开(公告)日：2022-09-22

申请号：US17684057

申请日：2022-03-01

申请人： Stealth BioTherapeutics Inc.

发明人： D. Travis Wilson

IPC分类号： A61K38/07 ,  A61K38/08 ,  A61K33/243 ,  A61K31/137 ,  A61K31/185 ,  A61K31/337 ,  A61K31/366 ,  A61K31/4245 ,  A61K31/4748 ,  A61K31/55 ,  A61K31/7042 ,  A61P25/02

摘要： The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

公开(公告)号：US20220117979A1

公开(公告)日：2022-04-21

申请号：US17206374

申请日：2021-03-19

申请人： The Brain Health Project, LLC

发明人： Morris Notelovitz

IPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/4748 ,  A61K31/353 ,  A61K31/592 ,  A61K31/566 ,  G01N33/68

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US11273195B2

公开(公告)日：2022-03-15

申请号：US16198121

申请日：2018-11-21

申请人： Melaleuca, Inc.

发明人： Alexander B. Rabovsky ,  Stephanie Y. Nielson

IPC分类号： A61K36/68 ,  A61K31/221 ,  A23L33/10 ,  A23L33/105 ,  A23L33/15 ,  A23L33/175 ,  A61K9/20 ,  A61K9/48 ,  A61K31/12 ,  A61K31/14 ,  A61K31/355 ,  A61K31/4748 ,  A61K31/519

摘要： This document provides dietary supplement compositions. For example, dietary supplement compositions having an acetylcholinesterase inhibitor (e.g., huperzine A), a Bacopa monnieri extract, acetyl-L-carnitine or acetyl CoA, and a curcuminoid (e.g., curcumin) are provided.

公开(公告)号：US20210401831A1

公开(公告)日：2021-12-30

申请号：US17473860

申请日：2021-09-13

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/4748 ,  A61K31/138 ,  A61K9/00

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20210386729A1

公开(公告)日：2021-12-16

申请号：US17383634

申请日：2021-07-23

申请人： NOVARTIS AG

发明人： Michael BADMAN ,  Jin CHEN ,  Bryan LAFFITTE ,  Sam LINDGREN

IPC分类号： A61K31/46 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61P1/16

摘要： The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders. In one embodiment, the invention provides a pharmaceutical unit dosage form composition, comprising a compound of Formula (I) or a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof.

公开(公告)号：US20210361644A1

公开(公告)日：2021-11-25

申请号：US17394832

申请日：2021-08-05

申请人： RK Pharma Solutions LLC

发明人： Ravishanker Kovi ,  Jayaraman Kannappan ,  Swaminathan Ramamurthy ,  Baskaran Ayyanar ,  Ramesh Pawar ,  Gaurav Yadav ,  Ronak Patel ,  Dixit Panchal ,  Rhagu Kasu ,  Bhavesh Panchal

IPC分类号： A61K31/4748 ,  A61K9/08 ,  A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/10

摘要： Ready-to-use liquid parenteral formulations are provided that include trabectedin, at least one of a pharmaceutically acceptable solvent, and at least one pharmaceutically acceptable excipient or adjuvant.

公开(公告)号：US20210283152A1

公开(公告)日：2021-09-16

申请号：US17323901

申请日：2021-05-18

申请人： Rigel Pharmaceuticals, Inc.

发明人： Esteban Masuda ,  Vadim Markovtsov

IPC分类号： A61K31/675 ,  A61K31/245 ,  A61K31/155 ,  A61K31/4706 ,  A61K31/427 ,  A61K31/573 ,  A61K31/519 ,  A61K39/42 ,  A61K31/4748 ,  A61K31/7048 ,  A61P31/14

摘要： Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.